The Conversation (0)
ProMIS Neurosciences provided a corporate update to shareholders for the second quarter of 2017.
ProMIS Neurosciences (TSX:PMN) provided a corporate update to shareholders for the second quarter of 2017.
As quoted in the press release:
Commenting on the update, ProMIS Executive Chairman Eugene Williams stated: “We are pleased with the continued progress at ProMIS and remain confident that our monoclonal antibody programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta may lead to best in class therapies and significant long-term value creation”.
Click here to read the full press release.
Source: www.newswire.ca